SummitTX Capital’s Colgate-Palmolive CL Stock Holding History

SummitTX Capital’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-76,563	Closed	-$6.53M	–	818
2026 Q1	$6.53M	Buy	+76,563	New	+$6.82M	0.2%	125
2025 Q3	–	Sell	-7,544	Closed	-$686K	–	788
2025 Q2	$686K	Buy	+7,544	New	+$689K	0.03%	445

Other funds holding CL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SummitTX Capital's CL Position: Q2 2026 in Review

SummitTX Capital sold out of Colgate-Palmolive (CL) in Q2 2026, closing a stake of 76,563 shares — an estimated $6.53M sold.

SummitTX Capital first reported a position in CL in Q2 2025 and held it in 2 quarters. The position peaked at $6.53M in Q1 2026. 2,016 funds tracked by Wall St. Rank hold CL as of Q2 2026.

SummitTX Capital reported no remaining Colgate-Palmolive position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 76,563 Colgate-Palmolive shares in Q2 2026, an estimated $6.53M.
SummitTX Capital first reported a position in Colgate-Palmolive in Q2 2025 and held it in 2 quarters.
SummitTX Capital's Colgate-Palmolive position peaked at $6.53M in Q1 2026.
2,016 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.